Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, m and n are as defined in the specification, with an inhibitory effect of PD-L1 expression and an inhibitory effect of reduced production of IL-2 and a medicament useful for the treatment of a disease associated with the reduced immune function caused by the formation of PD-1/PD-L1 binding.

Abstract: The present invention provides a preventive or therapeutic agent for pulmonary hypertension, including a compound represented by the following formula (I) or a salt thereof: where: —A— represents —NH—, —S—, or —O—; R1 and R2 are identical to or different from each other, and each represent a hydrogen atom or an alkyl group; R3 represents a hydrogen atom, a halogen atom, or an alkyl group; R4 represents a hydrogen atom or an alkyl group; R5 represents a hydrogen atom or an alkyl group; R6 and R7 are identical to or different each other, and each represent a hydrogen atom, a halogen atom, or an alkyl group; and R6 and R7 may form an unsaturated hydrocarbon six-membered ring together with a carbon atom to which R6 is bonded and a carbon atom to which R7 is bonded.

Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, m and n are as defined in the specification, with an inhibitory effect of PD-L1 expression and an inhibitory effect of reduced production of IL-2 and a medicament useful for the treatment of a disease associated with the reduced immune function caused by the formation of PD-1/PD-L1 binding.

Abstract: The present invention provides a preventive or therapeutic agent for pulmonary hypertension, including a compound represented by the following formula (I) or a salt thereof: where: -A- represents —NH—, —S—, or —O—; R1 and R2 are identical to or different from each other, and each represent a hydrogen atom or an alkyl group; R3 represents a hydrogen atom, a halogen atom, or an alkyl group; R4 represents a hydrogen atom or an alkyl group; R5 represents a hydrogen atom or an alkyl group; R6 and R7 are identical to or different each other, and each represent a hydrogen atom, a halogen atom, or an alkyl group; and R6 and R7 may form an unsaturated hydrocarbon six-membered ring together with a carbon atom to which R6 is bonded and a carbon atom to which R7 is bonded.

Abstract: The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula: wherein R1, R2, R3, R4, R5, R6, R7, m, n, p, X, and Y are as defined in the specification, a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a medicament useful for treatment and/or prevention of cancer, a vaccine adjuvant, and an inhibitor of immune checkpoint comprising a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein Bonds a-d, Ring A, R1, R1?, R2, R2?, R3-R8, and n are as defined in the present specification.

Abstract: The present invention provides a medicament useful for treatment and/or prevention of cancer, a vaccine adjuvant, and an inhibitor of immune checkpoint comprising a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein Bonds a-d, Ring A, R1, R1?, R2, R2?, R3-R8, and n are as defined in the present specification.

Abstract: The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula: wherein R1, R2, R3, R4, R5, R6, R7, m, n, p, X, and Y are as defined in the specification, a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. The osteopontin production inhibitor contains a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by Chemical Formula 1 or 2, and the dihydrodictyopyrone derivative is preferably a compound represented by Chemical Formula 3 or 4.

Abstract: Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. The osteopontin production inhibitor contains a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by Chemical Formula 1 or 2, and the dihydrodictyopyrone derivative is preferably a compound represented by Chemical Formula 3 or 4.

Abstract: An object of the present invention is to provide a pigment-type aqueous inkjet recording liquid capable of improving the clogging in nozzles and providing stable discharge, and having excellent physical properties required as an inkjet recoding liquid, in particular an OD value and wear-resistance. An aqueous inkjet recording liquid according to the present invention contains a polymer emulsion obtained by radically polymerizing a radically-polymerizable unsaturated monomer (a) containing radically-polymerizable unsaturated monomer having a specific amount of an alkoxysilyl group (a2) as an essential ingredient by using a specific amount of an emulsifier, water, and an aqueous polymerization initiator, and a pigment, in which a number of ultra-large particles of 1.5 ?m or greater in the polymer emulsion when converted to a solid content concentration 0.1% is 5.0×105/cm3 or fewer as measured by a particle counting method.

Abstract: An object of the present invention is to provide a pigment-type aqueous inkjet recording liquid capable of improving the clogging in nozzles and providing stable discharge, and having excellent physical properties required as an inkjet recoding liquid, in particular an OD value and wear-resistance. An aqueous inkjet recording liquid according to the present invention contains a polymer emulsion obtained by radically polymerizing a radically-polymerizable unsaturated monomer (a) containing radically-polymerizable unsaturated monomer having a specific amount of an alkoxysilyl group (a2) as an essential ingredient by using a specific amount of an emulsifier, water, and an aqueous polymerization initiator, and a pigment, in which a number of ultra-large particles of 1.5 ?m or greater in the polymer emulsion when converted to a solid content concentration 0.1% is 5.0×105/cm3 or fewer as measured by a particle counting method.

Abstract: Provided are a certain compounds and compositions useful for inhibiting or activating the production of various types of cytokines. Also provided are certain compounds and compositions for preventing or treating various diseases attributable to abnormal cytokine production or compromised immunity.